- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulations of vericiguat.
Symptomatic chronic cardiac failure with reduced ejection fraction
Treatment of symptomatic chronic heart failure in patients with reduced ejection fraction and are stabilised after IV therapy from a recent decompensation event.
Prior to commencing vericiguat therapy, care should be taken in order to optimise diuretic therapy and volume status to ensure patients are stabilised after the decompensation event, especially in patients with high NT-proBNP levels.
The starting dose is 2.5mg once daily. Every 2 weeks, the dose should be doubled to meet the target maintenance dose of 10mg once daily.
Patients with Renal Impairment
Vericiguat is not recommended in patients with eGFR <15 mL/minute/1.73m2 at treatment initiation or on dialysis.
Additional Dosage Information
In the event of tolerability issues by the patient, such as systolic blood pressure reading less than 90mmHg, temporary down-titration or discontinuation of vericiguat is advised.
Vericiguat may be crushed and mixed with water directly before administration for patients who are unable to swallow.
Children under 18 years
Systolic blood pressure below 100mmHg
Severe hepatic impairment
Precautions and Warnings
Glucose-galactose malabsorption syndrome
Left ventricular outflow obstruction
Renal impairment - eGFR below 15ml/minute/1.73m sq
Advise patient dizziness may affect ability to drive or operate machinery
Reduce dose or discontinue if excessive hypotension occurs
Female: Ensure adequate contraception during treatment
Advise patient not to take two doses on the same day if a dose is missed
Pregnancy and Lactation
Vericiguat is contraindicated during pregnancy.
Use of vericiguat is contraindicated by the manufacturer. At the time of writing, there is no data from the use of vericiguat in humans but animal studies have shown reproductive toxicity and therefore potential risk cannot be ruled out.
Vericiguat is contraindicated during breastfeeding.
Use of vericiguat during breastfeeding is contraindicated by the manufacturer. At the time of writing, there is no published information regarding the presence of vericiguat in human milk. However, vericiguat is present in the milk of lactating rats. Effects on exposed infants are unknown.
Gastroesophageal reflux disease
Last full review date: September 2021
Summary of Product Characteristics: Verquvo 2.5mg tablets. Bayer plc. Revised July 2021.
Summary of Product Characteristics: Verquvo 5mg tablets. Bayer plc. Revised July 2021.
Summary of Product Characteristics: Verquvo 10mg tablets. Bayer plc. Revised July 2021.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 14 June 2022
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.